Table 3 Review of literature
Study | Patient | Age | Gender | Species | Preceding Surgery/Event | Onset (days) | Recurrence | Intervention | Initial VA | Final VA | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
Irvine, 1992 [35] | 1 | NR | NR | P. cepacia | scleral laceration (trauma) | 12 | PPV/IOAB followed by chloramphenicol injection | 20/20 | Cleared infection | ||
Pathengay, 2005 [20] | 1 | 53 | M | B. cepacia | CE/IOL | 30 | Yes | PPV/PPL/IOAB/topicals | LP | NLP | Phthisis (LTFU after treatment of recurrence) |
Eser, 2006 [11] | 1 | 63 | M | B cepacia | CE/IOL | Unknown | IOAB/top, PPV/IOAB | 20/63 | Cleared infection, NVI | ||
2 | 72 | M | B cepacia | CE/IOL | 15 | IOAB/top, PPV/IOAB | HM | 20/50 | Cleared infection | ||
Sunenshine, 2009 [31] | 1 | 59–82 | M | B cepacia complex | CE/IOL (contaminated trypan blue) | 27 | Unknown | Unknown | |||
2 | 59–82 | M | B cepacia complex | CE/IOL (contaminated trypan blue) | 94 | Unknown | Unknown | ||||
(3–6) | 59–82 | M | Pseudomonas | CE/IOL (contaminated trypan blue) | 1 to 6 | Unknown | Unknown | ||||
Sachdeva, 2011 [26] | 1 | 80 | M | B. cepacia | CE/IOL | 180 | PPV/IOAB | LP | HM | Cleared infection, ERM | |
2 | 60 | M | B. cepacia | PK | 2 | PPV/IOAB | LP | 20/50 | Favorable, cleared infection | ||
3 | 65 | F | B. cepacia | CE/IOL | 5 | PPV/PPL/IOAB | LP | CF | Retinal detachment | ||
4 | 53 | M | B. cepacia | CE/IOL | 31 | PPV/PPL/IOAB | LP | NLP | Phthisis | ||
5 | 54 | M | B. cepacia | CE/IOL/Ant vitrectomy | 23 | PPV/IOAB | CF | 20/40 | Favorable, cleared infection | ||
6 | 80 | F | B. cepacia | CE/IOL | 35 | PPV/IOAB | 20/200 | 20/80 | Favorable, cleared infection | ||
7 | 7 | F | B. cepacia | trauma | 14 | PPV/PPL/IOAB | NLP | NLP | Evisceration | ||
8 | 45 | M | B. cepacia | CE/IOL | 13 | PPV/IOAB | CF | CF | Cleared infection, CNVM | ||
9 | 80 | M | B. cepacia | CE/IOL | 150 | PPV/IOAB | LP | 20/100 | Favorable, cleared infection | ||
10 | 60 | F | B. cepacia | CE/IOL | 10 | PPV/IOAB | LP | 20/160 | Favorable, cleared infection | ||
11 | 65 | M | B. cepacia | CE/IOL | 10 | PPV/IOAB | LP | LP | Retinal detachment | ||
12 | 33 | M | B. cepacia | trauma | 2 | PPV/PPL/IOAB removal | 20/60 | LP | Retinal detachment | ||
13 | 27 | F | B. cepacia | trauma | 2 | PPV/PPL/IOAB removal | LP | 20/20 | Favorable, cleared infection | ||
14 | 35 | M | B. cepacia | trauma | 3 | PPV/PPL/IOAB removal | LP | NLP | Phthisis | ||
Saffra, 2014 [27] | 1 | 91 | F | B. cepacia | IV ranizumab | 11 | PPV/IOAB, then ceftazidime | 20/60 | 20/30 | Cleared infection, CNVM | |
Lalitha, 2014 [12] | 1 | 69 | F | B. cepacia | CE/IOL | 15 | PPV/IOAB/SOI | HM | 20/200 | Cleared infection | |
2 | 46 | F | B. cepacia | CE/IOL | 13 | PPV/OAB/SOI | 20/80 | 20/200 | Cleared infection | ||
3 | 64 | F | B. cepacia | CE/IOL | 42 | PPV/IOAB/SOI | CF | CF | Cleared infection, persistent corneal infiltrate | ||
4 | 57 | M | B. cepacia | CE/IOL | 35 | PPV/IOAB/SOI | HM | LP | Tunnel infiltrate, failed patch graft | ||
5 | 61 | M | B. cepacia | CE/IOL | 16 | PPV/IOAB/SOI/EL | 6/18 | LP | Corneal infiltrate, edema, and stromal abscess | ||
6 | 66 | M | B. cepacia | CE/IOL | 23 | PPV/IOAB/SOI | CF | LP | Cleared infection | ||
7 | 43 | M | B. cepacia | CE/IOL | 33 | PPV/IOAB/SOI | 20/200 | 20/20 | Cleared infection, corneal infiltrate | ||
8 | 58 | F | B. cepacia | CE/IOL | 80 | PPV/IOAB/SOI | 20/80 | 20/80 | Cleared infection, TPK | ||
9 | 70 | F | B. cepacia | CE/IOL | 73 | PPV/IOAB/SOI | HM | 20/60 | Cleared infection | ||
10 | 61 | M | B. cepacia | CE/IOL | 45 | PPV/IOAB/SOI | 20/60 | 20/80 | Cleared infection, graft clear | ||
11 | 61 | M | B. cepacia | CE/IOL | 89 | PPV/IOAB/SOI | CF | 20/60 | Cleared infection, graft clear | ||
12 | 65 | M | B. cepacia | CE/IOL | 46 | PPV/IOAB/SOI | HM | 20/60 | Cleared infection, persistent tunnel infiltrate | ||
13 | 49 | F | B. cepacia | CE/IOL | 92 | PPV/IOAB/SOI | CF | 20/40 | Cleared infection, secondary glaucoma | ||
Deka, 2018 [6] | 1 | 68 | M | B. cepacia | CE/IOL | 14 | topical moxifloxacin/prednisone/atropine then 3d IAOB, 7d PPV/IOAB | Unknown | NLP | Phthisis | |
2 | 59 | F | B. cepacia | CE/IOL | 21 | Yes | IOAB, then PPV/IOAB | 20/200 | NLP | Evisceration | |
3 | 69 | M | B. cepacia | CE/IOL | 18 | IOAB | CF | 20/30 | Cleared infection | ||
Okonkwo, 2018 [17] | 1 | 34 | M | B cepacia | RD d/t PVR then PPV/SB/SOI | 7 | Yes | CE/SOR/PPV/IOAB | CF | NLP | Phthisis |
2 | 43 | M | B cepacia | RD d/t PVR then PPV/SB/SOI | 7 | Yes | PPV/SOR/PPV/IOAB | 20/120 | HM | PVR with hypotony | |
Okonkwo, 2020 [18] | 1 | 34 | F | B. cepacia | IV bevacizumab | 4 | Yes | IOAB/top, PPV/IOAB/SOI, PPV/PPL/IOAB | CF | 20/60 | Favorable, cleared infection |
Chen, 2021 [4] | 1 | 66 | F | B cepacia | none | Unknown | PPV/PPL/EL/SOI/IOAB | HM | 20/40 | Cleared infection | |
Deb, 2021 [7] | 1 | 69 | F | B cepacia complex | CE/IOL | 3 | Yes | IOAB then PPV/IOAB | CF | 20/120 | Cleared infection, CME + NVI |
2 | 58 | M | B cepacia complex | CE/IOL | 8 | IOAB then PPV/IOAB | 20/60 | 20/60 | Cleared infection | ||
3 | 69 | M | B cepacia complex | PKP | 20 | IOAB × 2 | LP | LP | Phthisis | ||
4 | 55 | F | B cepacia complex | CE/IOL | 22 | Yes | IOAB then PPV/IOAB | 20/120 | 20/60 | Cleared infection, secondary glaucoma | |
5 | 60 | M | B cepacia complex | CE/IOL | 17 | Yes | IOAB then PPV/IOAB | CF | 20/200 | Cleared infection, NVI | |
Lind, 2021 [14] | 1 | 73 | M | B. contaminans | CE/IOL | 13 | Yes | PPV/PPL/IOAB/POAb | 20/15 | Cleared infection | |
2 | 89 | M | B. contaminans | CE/IOL | 12 | Yes | PPV/PPL/IOAB/POAb | 20/22 | Cleared infection | ||
3 | 74 | M | B. contaminans | CE/IOL | 15 | Yes | PPV/IOAB/POAb | 20/20 | Cleared infection | ||
4 | 86 | M | B. contaminans | CE/IOL | 16 | Yes | PPV/PPL/IOAB/POAb | 20/20 | Cleared infection | ||
5 | 59 | F | B. contaminans | CE/IOL | 36 | PPV/PPL/IOAB/POAb | 20/25 | Cleared infection | |||
6 | 72 | M | B. contaminans | CE/IOL | 112 | Yes | PPV/PPL/IOAB/POAb | 20/25 | Cleared infection |